Targeted pill aims to stall a common brain Tumor's growth

NCT ID NCT07712757

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether the experimental drug safusidenib can slow or stop the growth of a type of slow-growing brain tumor called grade 2 glioma that has a specific genetic change (IDH1 mutation). Participants have had surgery but no other treatments like chemotherapy or radiation. Half receive safusidenib pills twice daily, and half receive a placebo, to see if the drug delays tumor progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
safusidenib
What this could lead to
If safusidenib works, it could offer a new treatment option that delays tumor progression for people with slow-growing IDH1-mutant gliomas, potentially postponing the need for chemotherapy or radiation.
What could go wrong
This is an early-stage Phase 3 trial with only 140 participants, so results may not apply to all patients. The drug may not improve outcomes or could cause side effects not yet fully understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.